Back to top
more

BioScrip, Inc. (BIOS)

(Delayed Data from NSDQ)

$1.98 USD

1.98
1,268,889

+0.05 (2.59%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.98 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife

The company achieved annualized supply chain improvement since the acquisition of Home Solutions.

    BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss

    BioScrip (BIOS) continues to disappoint in Q2 mainly due to its strategic shift to focus on growing its core revenue mix.

      Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant

      Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant

        BioScrip (BIOS) Strong on Infusion, Reimbursement a Drag

        On Jun 28, we issued an updated research report on Elmsford, NY-based BioScrip, Inc. (BIOS), a leading Infusion Service provider.

          Why Is BioScrip (BIOS) Up 15.3% Since the Last Earnings Report?

          BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip

            On May 10, we issued an updated research report on BioScrip, Inc. (BIOS ), a pure-play Infusion Service provider.

              BioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss

              BioScrip, Inc. (BIOS) reported net loss from continuing operations of $19.4 million or a loss of 18 cents per share in the first quarter of 2017 compared with net loss of $9.5 million or a loss of 17 cents a year ago.

                Why Is BioScrip (BIOS) Up 18.5% Since the Last Earnings Report?

                BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  BioScrip (BIOS) Stock Declines on Dull Q1 EBITDA Outlook

                  Bioscrip, Inc.'s (BIOS) shares witnessed a 2.2% fall in yesterday's trading session, closing at $1.78.

                    BioScrip (BIOS): Q4 Loss Narrower than Expected, Sales Top

                    BioScrip, Inc. (BIOS) reported net loss from continuing operations of $5.2 million or loss of 6 cents per share in the fourth quarter of 2016, much narrower than the year-ago net loss of $16.9 million or loss of 28 cents.